drugset
drugset / Trial / NCT00288639

Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).

NCT00288639 ↗

Phase 4 Completed 98 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of study is to assess the clinical improvement (change in seizure frequency), safety, and tolerability of subjects with partial seizures following adjunctive therapy of pregabalin BID (150 to 600 mg/day titration) in addition to existing standards AEDs.

Timeline

Start
2005-12
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 300 mg —

Indications

epilepsy